Detailed Clinical Characteristics of the Patients With No Previous Chemotherapy
| Patient No. . | Sex/Age . | RF . | Prior AIDS . | CD4/μL . | p24/μL . | LDH . | Histology . | Extranodal Site . | Bulky . | BM . | Stage . | PS . | Response . | RT/Response . | Duration (mo) . | Survival (mo) . | Status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | (other than BM) . | . | . | . | . | . | . | . | . | . |
| 2 | M/48 | HO | OI | 139 | 0 | 470 | PTCL | — | − | + | IV | 2 | CR | — | 35+ | 36+ | A/W |
| 4 | F/38 | IVDU | — | 4.7 | 0 | 1380 | DLBCL | Epiglottis | − | + | IV | 2 | CR | — | 4.5 | 8 | D/L |
| 7 | M/42 | HO | OI | 522 | 33 | 810 | Burkitt | Pleura | − | − | IV | 3 | NR | — | — | 2 | D/L |
| 8 | M/29 | IVDU | OI | 32 | 0 | 959 | Burkitt | — | + | + | IV | 1 | CR | Yes/CR | 4 | 7 | D/L |
| 9 | F/34 | IVDU | — | 125 | NA | 1189 | DLBCL | — | + | − | II | 1 | PR | — | 2 | 12 | D/L |
| 10 | M/33 | IVDU | OI | 5.1 | 164 | 368 | DLBCL | — | + | − | II | 3 | PR | — | 2 | 4 | D/L |
| 11 | M/35 | IVDU | OI | 38.5 | 0 | 218 | DLBCL | Stomach | − | − | II-E | 2 | CR | — | 24 | 26 | D/WS |
| 12 | M/40 | IVDU | — | 16 | 0 | 490 | DLBCL | — | − | + | IV | 2 | CR | — | 7 | 9 | LFU |
| 13 | F/33 | HE | OI | 22 | 0 | 875 | U | Gluteus | − | − | I-E | 2 | NE | — | — | — | — |
| 14 | F/23 | HE | — | 70 | 90 | 140 | U | Liver | + | − | IV | 0 | PR | — | 2 | 18 | D/L |
| 16 | F/29 | HE | — | 55 | 16 | 563 | Burkitt | Uterine cervix | − | − | I-E | 1 | CR | — | 21+ | 23+ | A/W |
| 17 | M/33 | HO | OI | 313 | 0 | 391 | DLCBL | — | + | + | IV | 0 | PR | Yes/PR | 2 | 16+ | A/W |
| 18 | M/28 | IVDU | OI | 5 | 312 | 577 | PTCL | Skin | − | − | IV | 2 | CR | — | 6 | 8 | D/INF |
| 20 | M/35 | IVDU | OI | 80 | 221 | 900 | DLBCL | CNS | − | − | IV | 3 | NR | — | — | 4 | D/L |
| 21 | M/31 | IVDU | — | 300 | 0 | 586 | DLBCL | Stomach | − | − | II-E | 3 | PR | — | 1 | 10 | D/L |
| 22 | M/33 | IVDU | — | 364 | 0 | 1283 | DLBCL | Gut | + | − | IV | 0 | PR | Yes/PR | 2 | 13.5+ | A/W |
| 23 | M/35 | HE | — | 35 | ND | 307 | Burkitt | Stomach | + | − | IV | 2 | NR | — | — | 13+ | A/W |
| 25 | M/38 | HO | — | 98 | 130 | 3724 | ALC | — | − | + | IV | 1 | NR | — | — | 8+ | A/L |
| 27 | M/34 | IVDU | — | 395 | 17 | 402 | PTCL | Liver | − | − | IV | 1 | CR | — | 5+ | 7+ | A/W |
| 28 | M/30 | IVDU | — | 225 | 0 | 450 | Burkitt | Gut | + | − | IV | 3 | NE | — | — | — | — |
| 29 | M/36 | IVDU | — | 605 | 0 | 812 | Burkitt | Stomach | + | − | IV | 3 | CR | — | 4+ | 6+ | A/W |
| Patient No. . | Sex/Age . | RF . | Prior AIDS . | CD4/μL . | p24/μL . | LDH . | Histology . | Extranodal Site . | Bulky . | BM . | Stage . | PS . | Response . | RT/Response . | Duration (mo) . | Survival (mo) . | Status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | (other than BM) . | . | . | . | . | . | . | . | . | . |
| 2 | M/48 | HO | OI | 139 | 0 | 470 | PTCL | — | − | + | IV | 2 | CR | — | 35+ | 36+ | A/W |
| 4 | F/38 | IVDU | — | 4.7 | 0 | 1380 | DLBCL | Epiglottis | − | + | IV | 2 | CR | — | 4.5 | 8 | D/L |
| 7 | M/42 | HO | OI | 522 | 33 | 810 | Burkitt | Pleura | − | − | IV | 3 | NR | — | — | 2 | D/L |
| 8 | M/29 | IVDU | OI | 32 | 0 | 959 | Burkitt | — | + | + | IV | 1 | CR | Yes/CR | 4 | 7 | D/L |
| 9 | F/34 | IVDU | — | 125 | NA | 1189 | DLBCL | — | + | − | II | 1 | PR | — | 2 | 12 | D/L |
| 10 | M/33 | IVDU | OI | 5.1 | 164 | 368 | DLBCL | — | + | − | II | 3 | PR | — | 2 | 4 | D/L |
| 11 | M/35 | IVDU | OI | 38.5 | 0 | 218 | DLBCL | Stomach | − | − | II-E | 2 | CR | — | 24 | 26 | D/WS |
| 12 | M/40 | IVDU | — | 16 | 0 | 490 | DLBCL | — | − | + | IV | 2 | CR | — | 7 | 9 | LFU |
| 13 | F/33 | HE | OI | 22 | 0 | 875 | U | Gluteus | − | − | I-E | 2 | NE | — | — | — | — |
| 14 | F/23 | HE | — | 70 | 90 | 140 | U | Liver | + | − | IV | 0 | PR | — | 2 | 18 | D/L |
| 16 | F/29 | HE | — | 55 | 16 | 563 | Burkitt | Uterine cervix | − | − | I-E | 1 | CR | — | 21+ | 23+ | A/W |
| 17 | M/33 | HO | OI | 313 | 0 | 391 | DLCBL | — | + | + | IV | 0 | PR | Yes/PR | 2 | 16+ | A/W |
| 18 | M/28 | IVDU | OI | 5 | 312 | 577 | PTCL | Skin | − | − | IV | 2 | CR | — | 6 | 8 | D/INF |
| 20 | M/35 | IVDU | OI | 80 | 221 | 900 | DLBCL | CNS | − | − | IV | 3 | NR | — | — | 4 | D/L |
| 21 | M/31 | IVDU | — | 300 | 0 | 586 | DLBCL | Stomach | − | − | II-E | 3 | PR | — | 1 | 10 | D/L |
| 22 | M/33 | IVDU | — | 364 | 0 | 1283 | DLBCL | Gut | + | − | IV | 0 | PR | Yes/PR | 2 | 13.5+ | A/W |
| 23 | M/35 | HE | — | 35 | ND | 307 | Burkitt | Stomach | + | − | IV | 2 | NR | — | — | 13+ | A/W |
| 25 | M/38 | HO | — | 98 | 130 | 3724 | ALC | — | − | + | IV | 1 | NR | — | — | 8+ | A/L |
| 27 | M/34 | IVDU | — | 395 | 17 | 402 | PTCL | Liver | − | − | IV | 1 | CR | — | 5+ | 7+ | A/W |
| 28 | M/30 | IVDU | — | 225 | 0 | 450 | Burkitt | Gut | + | − | IV | 3 | NE | — | — | — | — |
| 29 | M/36 | IVDU | — | 605 | 0 | 812 | Burkitt | Stomach | + | − | IV | 3 | CR | — | 4+ | 6+ | A/W |
Abbreviations: HO, homosexual; HE, heterosexual; OI, opportunistic infection; BM, bone marrow; PTCL, peripheral T-cell lymphoma; ALC, anaplastic large-cell lymphoma; U, unclassified lymphoma; L, lymphoblastic lymphoma; ND, not done; NR, no response; NE, not evaluable; D/L, dead with lymphoma; A/W, alive and well; D/WS, dead with wasting syndrome; LFU, lost to follow-up; D/INF, dead with infection.